Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control studyShaji Sebastian, Neil Bradley, G Walker et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 39
P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFIB E Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Journal of Crohn s and Colitis|2019Cited by 5
833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: UnifiBruce E. Sands, William J. Sandborn, Laurent Peyrin‐Biroulet et al.|Gastroenterology|2019Cited by 3
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extensionSilvio Danese, Bruce E. Sands, Laurent Peyrin‐Biroulet et al.|Journal of Crohn s and Colitis|2020Cited by 3
Efficacy in Biologic Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderate-Severe Ulcerative Colitis: UNIFIBE Sands, WJ Sandborn, Laurent Peyrin‐Biroulet et al.|Zeitschrift für Gastroenterologie|2019Cited by 2